CCS1477-02: An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced haematological malignancies (Multiple Myeloma arm)

A new experimental drug called CCS1477 is being tested in around 90 UK patients whose blood cancers—including multiple myeloma, acute myeloid leukaemia, and non-Hodgkin lymphoma—have stopped responding to existing treatments. This matters because advanced haematological malignancies often become resistant to standard therapies, leaving patients with few options. The drug targets a protein involved in cancer cell growth, and the trial will assess its safety, how the body processes it, and whether it shrinks tumours or slows disease progression. The study runs across up to 10 UK hospitals and includes dose escalation and expansion phases. If CCS1477 proves safe and effective, it could become a new treatment option for patients with relapsed or refractory blood cancers—conditions where current drugs frequently fail. The results will determine whether the drug moves into larger, later-stage trials. For now, the research is an early-stage clinical test: it will not change practice immediately, but it provides the essential safety and efficacy data needed to decide whether CCS1477 is worth pursuing further.